Abstract
Serum antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein are surrogate markers of immune response. We evaluated antibody levels pre and post third vaccine (booster) and compared responses among different cancer-bearing and normal veterans. Both total and neutralizing antibody levels increased in most subjects after the booster, but the frequency and magnitude of responses were lower in patients with B-cell malignancies undergoing therapy. Neutralizing antibody responses to omicron variants were reduced relative to wild-type and other variants. Additional prevention and prophylactic measures are warranted for poor vaccine responders.
Keywords: IBCL, coronavirus, vaccine, antibodies, B-cell malignancies, cancer